BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Al-Batran SE, Goetze TO, Mueller DW, Vogel A, Winkler M, Lorenzen S, Novotny A, Pauligk C, Homann N, Jungbluth T, Reissfelder C, Caca K, Retter S, Horndasch E, Gumpp J, Bolling C, Fuchs KH, Blau W, Padberg W, Pohl M, Wunsch A, Michl P, Mannes F, Schwarzbach M, Schmalenberg H, Hohaus M, Scholz C, Benckert C, Knorrenschild JR, Kanngießer V, Zander T, Alakus H, Hofheinz RD, Roedel C, Shah MA, Sasako M, Lorenz D, Izbicki J, Bechstein WO, Lang H, Moenig SP. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI. BMC Cancer 2017;17:893. [PMID: 29282088 DOI: 10.1186/s12885-017-3918-9] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Puhr HC, Preusser M, Prager G, Ilhan-Mutlu A. New Treatment Options for Advanced Gastroesophageal Tumours: Mature for the Current Practice? Cancers (Basel) 2020;12:E301. [PMID: 32012895 DOI: 10.3390/cancers12020301] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Granieri S, Altomare M, Bruno F, Paleino S, Bonomi A, Germini A, Facciorusso A, Fagnani D, Bovo G, Cotsoglou C. Surgical treatment of gastric cancer liver metastases: Systematic review and meta-analysis of long-term outcomes and prognostic factors. Crit Rev Oncol Hematol 2021;163:103313. [PMID: 34044098 DOI: 10.1016/j.critrevonc.2021.103313] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Uggeri F, Ripamonti L, Pinotti E, Scotti MA, Famularo S, Garancini M, Gianotti L, Braga M, Romano F. Is there a role for treatment-oriented surgery in liver metastases from gastric cancer? World J Clin Oncol 2020; 11(7): 477-494 [PMID: 32821653 DOI: 10.5306/wjco.v11.i7.477] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 D'Ugo D, Agnes A, Grieco M, Biondi A, Persiani R. Global updates in the treatment of gastric cancer: a systematic review. Part 2: perioperative management, multimodal therapies, new technologies, standardization of the surgical treatment and educational aspects. Updates Surg 2020;72:355-78. [PMID: 32306277 DOI: 10.1007/s13304-020-00771-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Kassar S, Samaha R, Aoun R, Khoury M, Kattan J. The concept of oligometastatic disease in gastric cancer: reality or fiction? Future Oncol 2022;18:135-8. [PMID: 34889659 DOI: 10.2217/fon-2021-1315] [Reference Citation Analysis]
6 Beckert S, Königsrainer A. Oligometastasierung beim Magen- und Ösophaguskarzinom: Aktuelle Studienlage und chirurgische Konzepte. Chirurg 2018;89:505-9. [DOI: 10.1007/s00104-018-0645-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
7 Luo Z, Rong Z, Huang C. Surgery Strategies for Gastric Cancer With Liver Metastasis. Front Oncol 2019;9:1353. [PMID: 31921626 DOI: 10.3389/fonc.2019.01353] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
8 Moentenich V, Gebauer F, Comut E, Tuchscherer A, Bruns C, Schroeder W, Buettner R, Alakus H, Loeser H, Zander T, Quaas A. Claudin 18.2 expression in esophageal adenocarcinoma and its potential impact on future treatment strategies. Oncol Lett 2020;19:3665-70. [PMID: 32391091 DOI: 10.3892/ol.2020.11520] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Bonnot PE, Lintis A, Mercier F, Benzerdjeb N, Passot G, Pocard M, Meunier B, Bereder JM, Abboud K, Marchal F, Quenet F, Goere D, Msika S, Arvieux C, Pirro N, Wernert R, Rat P, Gagnière J, Lefevre JH, Courvoisier T, Kianmanesh R, Vaudoyer D, Rivoire M, Meeus P, Villeneuve L, Piessen G, Glehen O; FREGAT and BIG-RENAPE Networks . Prognosis of poorly cohesive gastric cancer after complete cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (CYTO-CHIP study). Br J Surg 2021;108:1225-35. [PMID: 34498666 DOI: 10.1093/bjs/znab200] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Fujitani K, Kurokawa Y, Takeno A, Kawabata R, Omori T, Imamura H, Hirao M, Endo S, Kawada J, Moon JH, Kobayashi N, Takahashi T, Yamasaki M, Takiguchi S, Mori M, Eguchi H, Doki Y; Osaka University Clinical Research Group for Gastroenterological Surgery. Prospective Multicenter Interventional Study of Surgical Resection for Liver Metastasis from Gastric Cancer: R0 Resection Rate, and Operative Morbidity and Mortality. Ann Surg Oncol 2021. [PMID: 34480277 DOI: 10.1245/s10434-021-10750-3] [Reference Citation Analysis]
11 Jung MK, Schmidt T, Chon SH, Chevallay M, Berlth F, Akiyama J, Gutschow CA, Mönig SP. Current surgical treatment standards for esophageal and esophagogastric junction cancer.Ann N Y Acad Sci. 2020;1482:77-84. [PMID: 32798235 DOI: 10.1111/nyas.14454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Jung MK, Ott K, Chevallay M, Mönig SP. [Treatment options for oligometastatic gastric cancer]. Chirurg 2021;92:515-21. [PMID: 33544151 DOI: 10.1007/s00104-021-01353-5] [Reference Citation Analysis]
13 Gockel I, Lordick F. [Neoadjuvant chemotherapy for gastric cancer. Frequent overtreatment or meaningful concept?]. Chirurg 2020;91:384-90. [PMID: 32112151 DOI: 10.1007/s00104-020-01141-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Berlth F, Hoelscher AH. History of Esophagogastric Junction Cancer Treatment and Current Surgical Management in Western Countries. J Gastric Cancer 2019;19:139-47. [PMID: 31245158 DOI: 10.5230/jgc.2019.19.e18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
15 Jeene PM, van Laarhoven HWM, Hulshof MCCM. The role of definitive chemoradiation in patients with non-metastatic oesophageal cancer. Best Pract Res Clin Gastroenterol 2018;36-37:53-9. [PMID: 30551857 DOI: 10.1016/j.bpg.2018.11.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
16 Runkel M, Verst R, Spiegelberg J, Fichtner-Feigl S, Hoeppner J, Glatz T. Perioperative FLOT chemotherapy plus surgery for oligometastatic esophagogastric adenocarcinoma: surgical outcome and overall survival. BMC Surg 2021;21:35. [PMID: 33435947 DOI: 10.1186/s12893-020-01035-9] [Reference Citation Analysis]
17 Irino T, Matsuda S, Wada N, Kawakubo H, Kitagawa Y. Essential updates 2019/2020: Perioperative and surgical management of gastric cancer. Ann Gastroenterol Surg 2021;5:162-72. [PMID: 33860136 DOI: 10.1002/ags3.12438] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Schurink B, Mazza E, Ruurda JP, Roeling TAP, Bleys RLAW, van Hillegersberg R. Metastatic incidence of (PET)CT positive lung hilar and retroperitoneal lymph nodes in esophageal cancer patients. Surg Oncol 2020;33:170-6. [PMID: 32561084 DOI: 10.1016/j.suronc.2020.02.012] [Reference Citation Analysis]
19 Seesing MFJ, van der Veen A, Brenkman HJF, Stockmann HBAC, Nieuwenhuijzen GAP, Rosman C, van den Wildenberg FJH, van Berge Henegouwen MI, van Duijvendijk P, Wijnhoven BPL, Stoot JHMB, Lacle M, Ruurda JP, van Hillegersberg R; Gastroesophageal Metastasectomy Group. Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer: a nationwide study. Dis Esophagus 2019;32:doz034. [PMID: 31220859 DOI: 10.1093/dote/doz034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Bonnot P, Piessen G, Kepenekian V, Decullier E, Pocard M, Meunier B, Bereder J, Abboud K, Marchal F, Quenet F, Goere D, Msika S, Arvieux C, Pirro N, Wernert R, Rat P, Gagnière J, Lefevre JH, Courvoisier T, Kianmanesh R, Vaudoyer D, Rivoire M, Meeus P, Passot G, Glehen O; on behalf of the FREGAT and BIG-RENAPE Networks. Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis. JCO 2019;37:2028-40. [DOI: 10.1200/jco.18.01688] [Cited by in Crossref: 73] [Cited by in F6Publishing: 39] [Article Influence: 24.3] [Reference Citation Analysis]
21 Tchelebi LT, Goodman KA. Mature Experiences Using Local Therapy for Oligometastases. Semin Radiat Oncol 2021;31:180-5. [PMID: 34090644 DOI: 10.1016/j.semradonc.2021.02.003] [Reference Citation Analysis]
22 Diniz TP, da Costa WL Jr, Gomes CC, de Jesus VHF, Felismino TC, Torres SM, Ribeiro HSC, Diniz AL, de Godoy AL, de Farias IC, Dias-Neto E, Curado MP, Coimbra FJF. Symptomatic Recurrence and Survival Outcomes After Curative Treatment of Gastric Cancer: Does Intensive Follow-up Evaluation Improve Survival? Ann Surg Oncol 2021. [PMID: 34782973 DOI: 10.1245/s10434-021-10724-5] [Reference Citation Analysis]
23 Rogers MP, DeSantis AJ, DuCoin CG. Oligometastatic Adenocarcinoma of the Esophagus: Current Understanding, Diagnosis, and Therapeutic Strategies. Cancers (Basel) 2021;13:4352. [PMID: 34503162 DOI: 10.3390/cancers13174352] [Reference Citation Analysis]
24 Mielko J, Rawicz-Pruszyński K, Skórzewska M, Ciseł B, Pikuła A, Kwietniewska M, Gęca K, Sędłak K, Kurylcio A, Polkowski WP. Conversion Surgery with HIPEC for Peritoneal Oligometastatic Gastric Cancer. Cancers (Basel) 2019;11:E1715. [PMID: 31684115 DOI: 10.3390/cancers11111715] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
25 Gebauer F, Damanakis AI, Popp F, Quaas A, Kütting F, Lutz K, Held S, Deuß B, Göser T, Waldschmidt D, Bruns C. Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC). BMC Cancer 2021;21:1239. [PMID: 34794396 DOI: 10.1186/s12885-021-08966-3] [Reference Citation Analysis]
26 Dijksterhuis WPM, Verhoeven RHA, Slingerland M, Haj Mohammad N, de Vos-Geelen J, Beerepoot LV, van Voorthuizen T, Creemers GJ, van Oijen MGH, van Laarhoven HWM. Heterogeneity of first-line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real-world evidence study. Int J Cancer. 2020;146:1889-1901. [PMID: 31340065 DOI: 10.1002/ijc.32580] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
27 Ronellenfitsch U, Klose J, Kleeff J. Multimodal Therapy of Upper Gastrointestinal Malignancies. Cancers (Basel) 2021;13:793. [PMID: 33672858 DOI: 10.3390/cancers13040793] [Reference Citation Analysis]
28 Fonseca GM, Braghiroli MIFM, Pirola Kruger JA, Coelho FF, Herman P. Is There a Role for Locoregional Therapies for Non-colorectal Gastrointestinal Malignancies? Surg Oncol Clin N Am 2021;30:125-42. [PMID: 33220801 DOI: 10.1016/j.soc.2020.08.004] [Reference Citation Analysis]
29 Xu H, Zhang L, Miao J, Liu S, Liu H, Jia T, Zhang Q. Patterns of recurrence in adenocarcinoma of the esophagogastric junction: a retrospective study. World J Surg Oncol 2020;18:144. [PMID: 32593312 DOI: 10.1186/s12957-020-01917-5] [Reference Citation Analysis]
30 Kinoshita J, Yamaguchi T, Moriyama H, Fushida S. Current status of conversion surgery for stage IV gastric cancer. Surg Today 2021. [PMID: 33486610 DOI: 10.1007/s00595-020-02222-0] [Reference Citation Analysis]
31 Schizas D, Mylonas KS, Kapsampelis P, Bagias G, Katsaros I, Frountzas M, Hemmati P, Liakakos T. Patients undergoing surgery for oligometastatic oesophageal cancer survive for more than 2 years: bootstrapping systematic review data. Interactive CardioVascular and Thoracic Surgery 2020;31:299-304. [DOI: 10.1093/icvts/ivaa116] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Jezerskyte E, Saadeh LM, Hagens ERC, Sprangers MAG, Noteboom L, van Laarhoven HWM, Eshuis WJ, van Berge Henegouwen MI, Gisbertz SS. Long-Term Quality of Life After Total Gastrectomy Versus Ivor Lewis Esophagectomy. World J Surg 2020;44:838-48. [PMID: 31732762 DOI: 10.1007/s00268-019-05281-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
33 Matsumoto C, Iwatsuki M, Morinaga T, Yamashita K, Nakamura K, Kurashige J, Eto K, Iwagami S, Baba Y, Yoshida N, Miyamoto Y, Baba H. Long-term survival after multidisciplinary treatments for advanced esophagogastric junction cancer. Int Cancer Conf J 2021;10:207-11. [PMID: 34221833 DOI: 10.1007/s13691-021-00480-4] [Reference Citation Analysis]
34 Neumann PA, Berlet MW, Friess H. Surgical oncology in the age of multimodality therapy for cancer of the upper and lower gastrointestinal tract. Expert Rev Anticancer Ther 2021;21:511-22. [PMID: 33355020 DOI: 10.1080/14737140.2021.1868991] [Reference Citation Analysis]
35 Götze TO, Piso P, Lorenzen S, Bankstahl US, Pauligk C, Elshafei M, Amato G, Reim D, Bechstein WO, Königsrainer A, Mönig SP, Rau B, Schwarzbach M, Al-Batran SE. Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III "PREVENT"- (FLOT9) trial of the AIO /CAOGI /ACO. BMC Cancer 2021;21:1158. [PMID: 34715810 DOI: 10.1186/s12885-021-08872-8] [Reference Citation Analysis]
36 Mönig S, van Hootegem S, Chevallay M, Wijnhoven BPL. The role of surgery in advanced disease for esophageal and junctional cancer. Best Pract Res Clin Gastroenterol 2018;36-37:91-6. [PMID: 30551863 DOI: 10.1016/j.bpg.2018.11.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
37 Ghidini M, Petrillo A, Salati M, Khakoo S, Varricchio A, Tomasello G, Grossi F, Petrelli F. Surgery or Locoregional Approaches for Hepatic Oligometastatic Pancreatic Cancer: Myth, Hope, or Reality? Cancers (Basel). 2019;11. [PMID: 31374916 DOI: 10.3390/cancers11081095] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
38 Marte G, Tufo A, Steccanella F, Marra E, Federico P, Petrillo A, Maida P. Efficacy of Surgery for the Treatment of Gastric Cancer Liver Metastases: A Systematic Review of the Literature and Meta-Analysis of Prognostic Factors. J Clin Med 2021;10:1141. [PMID: 33803135 DOI: 10.3390/jcm10051141] [Reference Citation Analysis]
39 Zhao Y, Li J, Li D, Wang Z, Zhao J, Wu X, Sun Q, Lin PP, Plum P, Damanakis A, Gebauer F, Zhou M, Zhang Z, Schlösser H, Jauch KW, Nelson PJ, Bruns CJ. Tumour biology and multidisciplinary strategies of oligometastasis in gastrointestinal cancers.Semin Cancer Biol. 2020;60:334-343. [PMID: 31445220 DOI: 10.1016/j.semcancer.2019.08.026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
40 Galata C, Wimmer E, Kasper B, Wenz F, Reißfelder C, Jakob J. Multidisciplinary Tumor Board Recommendations for Oligometastatic Malignancies: A Prospective Single-Center Analysis. Oncol Res Treat 2019;42:87-94. [PMID: 30814474 DOI: 10.1159/000495474] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
41 Gertsen EC, Brenkman HJF, Goense L, Mohammad NH, Weusten BLA, van Hillegersberg R, Ruurda JP; Dutch Upper Gastrointestinal Cancer Audit (DUCA) group. Non-curative gastrectomy for advanced gastric cancer does not result in additional risk of postoperative morbidity compared to curative gastrectomy. Surg Oncol 2020;35:126-31. [PMID: 32871547 DOI: 10.1016/j.suronc.2020.08.018] [Reference Citation Analysis]
42 Wu P, Wang P, Ma B, Yin S, Tan Y, Hou W, Wang Z, Xu H, Zhu Z. Palliative gastrectomy plus chemotherapy versus chemotherapy alone for incurable advanced gastric cancer: a meta-analysis. Cancer Manag Res 2018;10:4759-71. [PMID: 30464590 DOI: 10.2147/CMAR.S179368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
43 Weiss ARR, Donlon NE, Schlitt HJ, Hackl C. Resection of oesophageal and oesophagogastric junction cancer liver metastases - a summary of current evidence. Langenbecks Arch Surg 2021. [PMID: 34860291 DOI: 10.1007/s00423-021-02387-3] [Reference Citation Analysis]
44 Petrillo A, Pompella L, Tirino G, Pappalardo A, Laterza MM, Caterino M, Orditura M, Ciardiello F, Lieto E, Galizia G, Castoro C, De Vita F. Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions. Cancers (Basel) 2019;11:E399. [PMID: 30901943 DOI: 10.3390/cancers11030399] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
45 Goetze OT, Al-Batran SE, Chevallay M, Mönig SP. Multimodal treatment in locally advanced gastric cancer. Updates Surg 2018;70:173-9. [PMID: 29946806 DOI: 10.1007/s13304-018-0539-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
46 Takeda FR, Kodama Pertille Ramos MF, Pereira MA, Muniz RR, Tustumi F, Biachi de Castria T, Aissar Sallum RA, Zilberstein B, Junior UR, Cecconello I. Predictive factors of recurrence in adenocarcinoma of the esophagogastric junction in the multimodal era. Am J Surg 2021;221:631-6. [PMID: 32862976 DOI: 10.1016/j.amjsurg.2020.07.031] [Reference Citation Analysis]
47 Jung JO, Nienhüser H, Schleussner N, Schmidt T. Oligometastatic Gastroesophageal Adenocarcinoma: Molecular Pathophysiology and Current Therapeutic Approach. Int J Mol Sci 2020;21:E951. [PMID: 32023907 DOI: 10.3390/ijms21030951] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
48 Kitano T, Aisu Y, Yasukawa D, Hori T. Aggressive Graphic/Surgical R0 Resection and Jejunal Interposition with Preservation of Mesojejunal Autonomic Nerves in Patients with Stage IV Esophagogastric Junction Adenocarcinoma: A Report of 3 Cases. Am J Case Rep. 2019;20:465-473. [PMID: 30952831 DOI: 10.12659/ajcr.913960] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
49 Dineen SP, Pimiento JM. The Landmark Series: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) for Treatment of Gastric Cancer Metastatic to Peritoneum. Ann Surg Oncol 2021;28:4130-7. [PMID: 33856601 DOI: 10.1245/s10434-021-09927-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Agnes A, Biondi A, Laurino A, Persiani R, D'Ugo D. Global updates in the treatment of gastric cancer: a systematic review. Part 1: staging, classification and surgical treatment. Updates Surg 2020;72:341-53. [PMID: 32157635 DOI: 10.1007/s13304-020-00736-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]